Sino Biological, Inc. has introduced 4RISE™, a suite of high-throughput wet-lab validation services designed to accelerate the development of AI-designed protein binders. The announcement addresses a critical bottleneck in AI-driven drug discovery: while computational design can rapidly generate novel protein binders, experimental validation is essential to confirm that these designs actually interact with their intended targets. By providing rapid, scalable, and data-rich validation, 4RISE™ aims to shorten design cycles and help researchers translate promising computational discoveries into real-world applications.
Central to the service is Sino Biological's XPressMAX™ Cell-Free Protein Synthesis (CFPS) platform, which enables recombinant protein synthesis in just three hours, with expression success rates exceeding 99% in established workflows. The platform supports a range of formats, including miniproteins, VHHs, scFvs, Fabs, enzymes, and cytokines, allowing rapid testing of AI-designed candidates. Combined with high-throughput binding analysis using Carterra SPR, Biacore SPR, and Octet BLI, the workflow can deliver sequence-to-AI-ready binding data in as little as three days. Structured binding data are accessible in real time via API, enabling seamless integration into downstream research and iterative design-test-learn cycles.
The 4RISE™ offering includes four rapid screening services tailored to different stages of binder discovery. Rapid Hit Discovery identifies binding-positive miniproteins and VHHs through crude-supernatant screening. Comparative Binder Screening evaluates purified candidates under standardized conditions to support prioritization. Affinity and Kinetic Characterization provides quantitative binding insights for lead selection, while Specialized Binder Expression and Validation supports diverse binder formats through tailored mammalian expression and binding analysis. Beyond binding, the services include more than 20 developability assays, over 1,000 protein bioactivity assays, and more than 10 cell-based functional assays, enabling in-depth candidate evaluation and design optimization.
Sino Biological has already collaborated with AI companies on wet-lab validation for AI-designed antibody discovery, de novo binder design, and computational protein engineering. The company reports that its 4RISE™ validation has supported studies published in high-impact journals such as Science, Nature Communications, and Scientific Reports. "AI-designed molecules need reliable wet-lab experimental evidence to demonstrate their potential," said Dr. Rob Burgess, Chief Business Officer at Sino Biological US, Inc. "Our integrated capabilities provide the high-quality data researchers need to evaluate candidates quickly, shorten design cycles, and turn promising discoveries into real-world applications."
For AI-focused life sciences researchers, the launch signals a move toward more integrated workflows that connect computational design with experimental validation. The ability to obtain AI-ready binding data in days rather than weeks could significantly reduce the time and cost associated with screening large libraries of AI-generated candidates. Researchers interested in the service can explore 4RISE™ High-Throughput Wet-Lab Validation Services to learn more about the available workflows. The full announcement is available via NEWMEDIAWIRE.


